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Background
The failure of conventional therapy to cure multiple mye-
loma has led investigators to test the effectiveness of high
dose chemotherapy and hematopoietic stem cell trans-
plantation. The objective of this study was to determine
the mortality and morbidity in patients with multiple
myeloma treated with hematopoietic stem cell transplan-
tation at our institution.
Materials and methods
We reviewed the charts of patients with multiple mye-
loma, who received high dose chemotherapy and hemat-
opoietic stem cell transplantation, at the Instituto
Nacional de Cancerologia from 1991 to march 2006. We
recorded the demographic variables, the type of trans-
plant, the conditioning regimen, number of CD34+ cells
transfused, number of platelets and red blood cells trans-
fusions, neutropenia and thrombocytopenia duration.
We also analyzed the adverse events related to the proce-
dure.
Results
We did 18 peripheral blood stem cell transplants in 14
patients with MM, from 1991 to march 31, 2006. Nine
were female and five male. Median age was 51.5 years
(range 38 to 63 years). Regarding the monoclonal protein,
10 cases were IgG (5 lambda and 5 kappa), 2 IgA (1 kappa
and 1 lambda), and 2 cases light chain (1 lambda and 1
kappa). Ten patients had stage II. Treatment before the
transplant consisted in 1 to 4 chemotherapy regimens,
mainly VAD, melphalan-prednisone and thalidomide-
dexamethasone. In 3 patients the transplant was alloge-
neic and in 11 autologous, 4 patients had a second trans-
plant (tandem). We used filgrastim for stem cell
movilization, and in 1 patient filgrastim and cyclophos-
phamide. The cells were collected with a standard apher-
esis procedure. Median CD34+ cells transplanted were
2.04 × 106/Kg. In the autologous setting we used Melpha-
lan 200/m2 (po) and in the case of the allotrasplant 2
cases were conditioned with Busulfan-cyclophosphamide
and 1 patient with BEAM and Alemtuzumab. The median
time to achieve >500/mm3 neutrophils in the patients
with tandem transplants was 4 days for the first procedure
and 7 for the second, in the patients with 1 autologous
transplant the median time was 13 days and for the
patients with allogeneic transplant was 21 days. Median
time to >20 000/mm3 platelets were, 8 and 9 days for the
tandem procedures, 14 days for the single autologous
transplant and 22 days for the allogeneic transplant. The
patients with autologous transplant received form 0 to 3
pack red cells and from 1 to 4 platelets transfusions. The
most frequent significant adverse event was infection.
One patient died of cerebral hemorrhage on day +6, in the
allotransplant group, No transplant related deaths
ocurred in the autotransplant group.
from 24th Annual Meeting of the National Cancer Institute of Mexico
Mexico City, Mexico. 14–17 February 2007
Published: 5 February 2007
BMC Cancer 2007, 7(Suppl 1):A42 doi:10.1186/1471-2407-7-S1-A42
<supplement> <title> <p>24<sup>th </sup>Annual Meeting of the National Cancer Institute of Mexico</p> </title> <editor>Alfonso Duenas-Gonzalez, Dolores Gallardo-Rincon, Luis A Herrera, Myrna Candelaria, Adolfo Fuentes-Alburo</editor> <note>Meeting abstracts – A single PDF containing all  abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1471-2407-7-S1-full.pdf">here</a>.</note> </supplement>
This article is available from: http://www.biomedcentral.com/1471-2407/7/S1/A42
© 2007 Garcia et al; licensee BioMed Central Ltd. Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2007, 7(Suppl 1):A42 http://www.biomedcentral.com/1471-2407/7/S1/A42
Page 2 of 2
(page number not for citation purposes)
Conclusion
Autologous transplant conditioned with oral melphalan
in patients with MM is a very safe procedure when per-
formed at the INCAN. Infections are frequent and com-
monly related to the venous access. Allotransplants have a
high mortality.